Topic: non-small cell lung cancer
BMS' Opdivo is finally under FDA consideration as a therapy for previously untreated lung cancer.
Opdivo goes directly to the lucrative lung cancer market with its first nod in China, where nearly 800,000 new patients are diagnosed each year.
After making headlines at this year’s American Society of Clinical Oncology annual meeting, Merck’s Keytruda had a big week on the other side of the pond, too.
Many ASCO-watchers crowned Merck's Keytruda as king of the lung cancer market, but rivals Roche and BMS are kicking back.
Merck’s Keytruda has a solo OK for first-line lung cancer patients whose tumors bear high levels of PD-L1. But that group will likely soon get bigger.
At this year's ASCO, squamous lung cancer has elbowed nonsquamous disease off center stage—but once again, it's Merck & Co. stealing the spotlight.
Despite some trial setbacks, Bristol-Myers' Opdivo still leads the I-O pack by U.S. revenue. But wins for rival Keytruda could change that soon.
Looks like Merck’s Keytruda could get some company in the lung cancer chemo-combo department.
Drugmakers have hoped that pairing their cancer drugs with I-O treatments would improve benefits. Not for Genmab and J&J.
Imfinzi already is I-O's only FDA-approved maintenance therapy in lung cancer. Friday, the AZ med hit another benchmark to stretch out that lead.